Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PORCN | Q9H237 | 10/20 | 0.55 |
| ▸ | WNT3A | P56704 | 8/20 | 0.55 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30007910 | 1.00 | PORCN (0.55) | PORCNWNT3APTK2 | |
| SCHEMBL22989737 | 0.84 | PORCN (0.54) | PORCNWNT3A | |
| SCHEMBL17675613 | 0.84 | WNT3A (0.61) | PORCNWNT3A | |
| SCHEMBL3712178 | 0.83 | KMT2A (0.59) | WNT3A | |
| SCHEMBL17673081 | 0.81 | PORCN (0.60) | PORCNWNT3A | |
| SCHEMBL17675369 | 0.80 | PORCN (0.47) | PORCNWNT3A | |
| SCHEMBL17316889 | 0.79 | ABL1 (0.54) | PTK2 | |
| SCHEMBL22975368 | 0.78 | PTK2 (0.56) | WNT3APTK2 | |
| SCHEMBL22975369 | 0.78 | PTK2 (0.56) | PTK2 | |
| SCHEMBL4237518 | 0.76 | RAB9A (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3693476-B1 | CANCER PATIENT SELECTION FOR ADMINISTRATION OF WNT SIGNALING INHIBITORS USING RNF43 MUTATION STATUS | NOVARTIS AG (CH) | 2023-10-18 | — | — | EP | claimed |
| US-12202826-B2 | N-pyridinyl acetamide derivatives as inhibitors of the Wnt signaling pathway | REDX PHARMA PLC (GB) | 2025-01-21 | — | — | US | disclosed |
| US-20230365549-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | REDX PHARMA PLC (GB) | 2023-11-16 | — | — | US | disclosed |
| US-11643408-B2 | N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway | REDX PHARMA PLC (GB) | 2023-05-09 | — | — | US | disclosed |
| US-20230121489-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS WNT SIGNALLING PATHWAY INHIBITORS | REDX PHARMA PLC (GB) | 2023-04-20 | — | — | US | disclosed |
| US-11459326-B2 | N-pyridinyl acetamide derivatives as Wnt signalling pathway inhibitors | REDX PHARMA PLC (GB) | 2022-10-04 | — | — | US | disclosed |
| US-20210046076-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | REDX PHARMA PLC (GB) | 2021-02-18 | — | — | US | disclosed |
| US-20200407356-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS WNT SIGNALLING PATHWAY INHIBITORS | REDX PHARMA PLC (GB) | 2020-12-31 | — | — | US | disclosed |
| US-10793560-B2 | N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway | REDX PHARMA PLC (GB) | 2020-10-06 | — | — | US | disclosed |
| US-10793562-B2 | N-pyridinyl acetamide derivatives as Wnt signalling pathway inhibitors | REDX PHARMA PLC (GB) | 2020-10-06 | — | — | US | disclosed |
| US-20190144447-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS WNT SIGNALLING PATHWAY INHIBITORS | REDX PHARMA PLC (GB) | 2019-05-16 | — | — | US | disclosed |
| US-10202375-B2 | N-pyridinyl acetamide derivatives as Wnt signalling pathway inhibitors | REDX PHARMA PLC (GB) | 2019-02-12 | — | — | US | disclosed |
| US-20180319788-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | REDX PHARMA PLC (GB) | 2018-11-08 | — | — | US | disclosed |
| US-20170298062-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS WNT SIGNALLING PATHWAY INHIBITORS | REDX PHARMA PLC (GB) | 2017-10-19 | — | — | US | disclosed |
| US-20170275276-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | REDX PHARMA PLC (GB) | 2017-09-28 | — | — | US | disclosed |
| EP-3204378-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY | Redx Pharma PLC (GB) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016055786-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY | REDX PHARMA PLC (GB) | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202375-B2 | N-pyridinyl acetamide derivatives as Wnt signalling pathway inhibitors | WNT1, WNT3, CTNNB1 | PORCN 10/4885WNT3A 6/4885PTK2 1060/4885 |
| US-10793562-B2 | N-pyridinyl acetamide derivatives as Wnt signalling pathway inhibitors | WNT1, WNT3, CTNNB1 | PORCN 10/4885WNT3A 6/4885PTK2 1060/4885 |
| US-11459326-B2 | N-pyridinyl acetamide derivatives as Wnt signalling pathway inhibitors | WNT1, WNT3, CTNNB1 | PORCN 10/4885WNT3A 6/4885PTK2 1060/4885 |
| US-20230121489-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS WNT SIGNALLING PATHWAY INHIBITORS | WNT1, WNT3, CTNNB1 | PORCN 10/4885WNT3A 6/4885PTK2 1060/4885 |
| US-12202826-B2 | N-pyridinyl acetamide derivatives as inhibitors of the Wnt signaling pathway | WNT1, WNT3, CTNNB1 | PORCN 13/4885WNT3A 6/4885PTK2 1298/4885 |
| US-10793560-B2 | N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway | WNT1, WNT3, CTNNB1 | PORCN 9/4885WNT3A 6/4885PTK2 1197/4885 |
| US-20230365549-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | WNT1, WNT3, CTNNB1 | PORCN 13/4885WNT3A 6/4885PTK2 1298/4885 |
| US-20180319788-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | WNT1, WNT3, CTNNB1 | PORCN 9/4885WNT3A 6/4885PTK2 1197/4885 |
| US-20190144447-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS WNT SIGNALLING PATHWAY INHIBITORS | WNT1, WNT3, CTNNB1 | PORCN 10/4885WNT3A 6/4885PTK2 1060/4885 |
| US-20170298062-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS WNT SIGNALLING PATHWAY INHIBITORS | WNT1, WNT3, CTNNB1 | PORCN 10/4885WNT3A 6/4885PTK2 1060/4885 |
| US-20170275276-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | WNT1, WNT3, CTNNB1 | PORCN 9/4885WNT3A 6/4885PTK2 1197/4885 |
| US-20200407356-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS WNT SIGNALLING PATHWAY INHIBITORS | WNT1, WNT3, CTNNB1 | PORCN 10/4885WNT3A 6/4885PTK2 1060/4885 |
| US-20210046076-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | WNT1, WNT3, CTNNB1 | PORCN 13/4885WNT3A 6/4885PTK2 1298/4885 |
| US-11643408-B2 | N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway | WNT1, WNT3, CTNNB1 | PORCN 13/4885WNT3A 6/4885PTK2 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.